Merrill Downgrades Wyeth to 'Neutral'

Analyst David Risinger is concerned about litigation uncertainty surrounding the company's Fen-Phen diet drug

Merrill Lynch downgraded Wyeth (WYE ) to neutral from buy.

To continue reading this article you must be a Bloomberg Professional Service Subscriber.